Sepset Biosciences
Sepset Biosciences Inc. is a molecular diagnostics company developing a first-in-class in vitro diagnostic assay for early and rapid risk assessment of sepsis. Their innovative technology detects a unique gene expression signature based on the dysfunctional immune response rather than the presence of a pathogen, addressing the urgent need for faster and more accurate sepsis diagnosis. The company's mission is to improve patient survival and healthcare efficiency by enabling earlier intervention and targeted treatment for sepsis, a condition responsible for over 19 million deaths annually worldwide and significant healthcare costs.
Industries
Nr. of Employees
small (1-50)
Sepset Biosciences
Products
Blood-based sepsis diagnostic (in development)
A hospital-directed blood-based diagnostic under development to detect a sepsis-associated gene-expression signature and provide early risk assessment for progression to organ failure.
Blood-based sepsis diagnostic (in development)
A hospital-directed blood-based diagnostic under development to detect a sepsis-associated gene-expression signature and provide early risk assessment for progression to organ failure.
Services
Collaborative licensing and technology-transfer engagements to integrate a validated sepsis gene-expression signature onto clinical diagnostic platforms.
Collaborative licensing and technology-transfer engagements to integrate a validated sepsis gene-expression signature onto clinical diagnostic platforms.
Expertise Areas
- Molecular diagnostics
- Biomarker discovery and validation
- Prospective multi-center clinical validation
- Transcriptomics and gene expression analysis
Key Technologies
- Transcriptome profiling / gene expression signatures
- Blood-based molecular diagnostic assays
- Prospective observational clinical trials
- Meta-analysis and statistical validation methods
News & Updates
An article discussing the potential role of AI in improving sepsis survival rates, highlighting the misdiagnosis issues and the innovative diagnostic approaches by Sepset Biosciences.
An article about the research on sepsis endotypes and the importance of early identification and intervention, featuring Sepset's technology.
A breakthrough in sepsis detection using machine learning, developed by researchers at UBC, which Sepset Biosciences is building upon.
Discussion on how early sepsis detection can impact COVID-19 patient outcomes, emphasizing Sepset's technology.
A story about the personal motivation behind Sepset's technology, inspired by Olga Peña's loss of her father to sepsis.
Research on sepsis endotypes and the importance of early detection, with Sepset's contributions.
An article discussing the potential role of AI in improving sepsis survival rates, highlighting the misdiagnosis issues and the innovative diagnostic approaches by Sepset Biosciences.
An article about the research on sepsis endotypes and the importance of early identification and intervention, featuring Sepset's technology.
A breakthrough in sepsis detection using machine learning, developed by researchers at UBC, which Sepset Biosciences is building upon.
Discussion on how early sepsis detection can impact COVID-19 patient outcomes, emphasizing Sepset's technology.
A story about the personal motivation behind Sepset's technology, inspired by Olga Peña's loss of her father to sepsis.
Research on sepsis endotypes and the importance of early detection, with Sepset's contributions.